Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. BIOAF


Primary Symbol: V.BTI

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by Boomskidon Oct 05, 2023 10:12am
108 Views
Post# 35670890

RE:RE:RE:RE:RE:RE:RE:RE:RE:I sure like this Jon

RE:RE:RE:RE:RE:RE:RE:RE:RE:I sure like this JonThis is the lazy part about you, zwerp. There is lots of proof that xB3 works. We know that you won't read the literature but the Texas Tech and MedImmune scientific papers represent a good start. Denali is certainly proving that RMT is worth pursuing. It's market cap is still almost US$3 billion. That's because they did the work that Bioasis never even attempted to do in any meaningful way.

The most compelling proof of confidence in xB3 are the hoops that Rathjen, LT, and The Placee jumped through to acquire Bioasis. Why would they want it if it didn't work?

If xB3 (Bioasis) is sold, as I believe it will be soon, we'll have our proof of that confidence. Then we'll sit back and watch others make a lot of money from it.

About nobody picking up xB3 for nothing, that's what LT and The Placee tried to do. That's a fact, zwerp. The Midatech shareholders turned it down because their resulting ownership percentage of Biodexa was almost worthless. They had the smarts to turn the deal down, something Bioasis shareholders didn't do.

About a pharma picking up Bioasis for nothing, I don't believe that Rathjen would ever have allowed it. I suspect that any overtures from pharmas were extinguished by Bioasis. I suspect that she would have, or has, discouraged it. My guess is that no pharma would touch Bioasis after LT got their hooks into Rathjen. Total uncertainty was created by that relationship. And when xB3 was downplayed in Bioasis literature, Bioasis projects were shelved, and Cresence was acquired, my guess that the common feeling was that there is a problem with xB3.

Was the Cresence fiasco LT's idea? Was it the diversion that LT might have wanted in order to acquire xB3 for nothing? Did they know that the Bioasis share price would collapse because of that and because of the acquisition terms that would have left Bioasis shareholders with 3 or 4 percent of a Biodexa that sold off the xB3 platform, Rathjen, and Saltarelli to a private venture firm?

You're ignoring the facts, zwerp, mostly because you're too lazy to learn them. Further, you don't know enough to figure stuff out. This all went down like a Grisham novel, for goodness sakes. Maybe you should read some of them, too.

jd
<< Previous
Bullboard Posts
Next >>